GlassScriptPhysician profile
Rao S Pasupuleti
NPI 1891893541
$10,500.53
in general payments reported to CMS, 2019-2025
69 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,913 · 2020: $1,159 · 2021: $1,543 · 2022: $1,703 · 2023: $1,890 · 2024: $1,487 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,182.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $971.33 | 2019-2025 | Qelbree, Qelbree |
| Abbvie INC. | $888.19 | 2021-2025 | |
| Biogen, INC. | $815.40 | 2019-2025 | Vumerity, Tysabri |
| Emd Serono, INC. | $660.10 | 2019-2025 | Mavenclad |
| Corium, LLC | $641.11 | 2022-2025 | Azstarys, Adlarity |
| Ucb, INC. | $570.88 | 2019-2025 | Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $556.94 | 2019-2025 | |
| Tris Pharma INC | $514.23 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Sunovion Pharmaceuticals INC. | $330.01 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $328.55 | 2019-2022 | |
| Eisai INC. | $266.94 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $222.72 | 2019-2023 | Austedo, Austedo Xr |
| Neos Therapeutics, LP | $188.66 | 2019-2022 | |
| Neurelis, INC. | $183.05 | 2020-2025 | Valtoco |
| Ironshore Pharmaceuticals INC. | $181.85 | 2019-2024 | Jornay Pm |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rao Pasupuleti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.